Abstract:Background Recombinant human parathyroid hormone (1-34) (rhPTH (1-34)) is the first agent in a unique class of anabolic therapies acting on the skeleton. The efficacy and safety of long-term administration of rhPTH (1-34) in Chinese postmenopausal women had not been evaluated. This study compared the clinical efficacy and safety of rhPTH (1-34) with elcatonin for treating postmenopausal women with osteoporosis in 11 urban areas of China. Methods A total of 453 postmenopausal women with osteoporosis were enrolled in an 18-month, multi-center, randomized, controlled study. They were randomized to receive either rhPTH (1-34) 20 μg (200 U) daily for 18 months, or elcatonin 20 U weekly for 12 months. Lumbar spine (L1-4) and femoral neck bone mineral density (BMD), fracture rate, back pain as well as biochemical markers of bone turnover were measured. Adverse events were recorded. Results rhPTH (1-34) increased lumbar BMD significantly more than did elcatonin after 6, 12, and 18 months of treatment (4.3% vs. 1.9%, 6.8% vs. 2.7%, 9.5% vs. 2.9%, P <0.01). There was only a small but significant increase of femoral neck BMD after 18 months (2.6%, P <0.01) in rhPTH groups. There were larger increases in bone turnover markers in the rhPTH (1-34) group than those in the elcatonin group after 6, 12, and 18 months (serum bone-specific alkaline phosphatase (BSAP) 93.7% vs. -3.6%; 117.8% vs. -4.1%; 49.2% vs. -5.8%, P <0.01; urinary C-telopeptide/creatinine (CTX/Cr) 250.0% vs. -29.5%; 330.0% vs. -41.4%, 273.0% vs. -10.6%, P <0.01). rhPTH (1-34) showed similar effect of pain relief as elcatonin. The incidence of clinical fractures was 5.36% (6/112) in elcatonin group and 3.2% (11/341) in rhPTH (1-34) group (P=0.303). Both treatments were well tolerated. Hypercaluria (9.4%) and hypercalcemia (7.0%) in rhPTH (1-34) group were transient and caused no clinical symptoms. Pruritus (8.2% vs. 2.7%, P=0.044) and redness of injection site (4.4% vs. 0, P=0.024) were more frequent in rhPTH (1-34). Nausea/vomiting (16.1% vs. 6.2%, P=0.001) and hot flushes (7.1% vs. 0.6%, P <0.001) were more common in elcatonin group. Conclusions rhPTH (1-34) was associated with greater increases in lumbar spine BMD and bone formation markers. It could increase femoral BMD after 18 months of treatment. rhPTH could improve back pain effectively. The results of the present study indicate that rhPTH (1-34) is an effective, safe agent in treating Chinese postmenopausal women with osteoporosis. (ChiCTR-TRC-10000924)

[Bone alkaline phosphatase and N-MID osteocalcin in monitoring of osteoporosis treatment with recombinant human parathyroid hormone 1-34].

[The Study on the Inhibitive Effects of Recombinant Parathyroid Hormone (1-34) on Osteolysis in a Murine Calvarial Model Induced by Wear Particles].

The clinical value of BALP on diagnosis and treatment of osteoporosis in postmenopausal women

A randomized, multicenter, active-controlled trial to compare the efficacy of recombinant human parathyroid hormone (1-34) with that of elcatonin in postmenopausal women with osteoporosis in China]

Biomarkers as therapy monitoring for postmenopausal osteoporosis: a systematic review

Clinical Efficacy Observation of Recombinant Human Parathyroid Hormone 1-34(Rhpth1-34)combined with Caltrate D in Treatment of Post Menopausal Women with Osteoporosis

Diagnosis value of bone metabolic markers in primary osteoporosis

A Randomized, Multicenter Controlled Trial to Compare the Efficacy of Recombinant Human Parathyroid Hormone (1-34) with Elcatonin in Postmenopausal Women with Osteoporosis in China.

Potential of biomarkers during pharmacological therapy setting for postmenopausal osteoporosis: a systematic review

Comparison of Parathyroid Hormone (1-34) and Elcatonin in Postmenopausal Women with Osteoporosis: an 18-Month Randomized, Multicenter Controlled Trial in China.

Age-related Changes of Serum Bone Alkaline Phosphatase and Cross-Linked C-telopeptides of Type I Collagen and the Relationship with Bone Mineral Density in Chinese Women

High Alkaline Phosphatase and Low Intact Parathyroid Hormone Associate with Worse Clinical Outcome in Peritoneal Dialysis Patients

Correlation between Bone Turnover Markers and Bone Mineral Density in Patients Undergoing Long-Term Anti-Osteoporosis Treatment: A Systematic Review and Meta-Analysis

Evaluation of bone turnover by detecting serum beta-collagen degradation products and osteocalcin concentration

Practical Considerations for the Clinical Application of Bone Turnover Markers in Osteoporosis

Comparative analysis of bone turnover markers in bone marrow and peripheral blood: implications for osteoporosis

Effect of recombinant human parathyroid hormone on bone fracture healing in the rat observed by micro-CT

Effectiveness and Usefulness of Bone Turnover Marker in Osteoporosis Patients: A Multicenter Study in Korea

[Relationship Between Bone Markers and the Progression of Multiple Myeloma].

Clinical characteristics associated with bone mineral density improvement after 1-year alendronate/vitamin d3 or calcitriol treatment

Changes in Serum Receptor Activator of Nuclear Factor-κB Ligand, Osteoprotegerin, and Interleukin-6 Levels in Patients with Glucocorticoid-Induced Osteoporosis Treated with Human Parathyroid Hormone (1–34)